CogState (CGS.AX) Delnica Cena
CogState Cena
V zadnjih 19 letih so prihodki CogState rasli 20,0 % letno in dosegli 53,09 Mio. USD. Dobiček na delnico je rasel 8,5 % letno v zadnjih 16 letih. Za CogState je čista marža 19,1 % narasla v primerjavi s 16,0 % pred nekaj leti. Po današnji ceni je dividendna donosnost približno 1,12 %. Izplačilni delež je okoli 34 % dobička. Konsenzna 12-mesečna ciljna cena za CogState je 2,13 USD, približno pod tečaj za 16,2 %. Od 6 analitikov jih 5 priporoča nakup — skupni konsenz je Nakup.
Cena delnice CogState
Do teh podatkov prek Eulerpool API
100.000 zahtevkov/mes. brezplačno · brez kartice
CogState poslovni model in analiza delnice
Pogosto postavljena vprašanja o delnici CogState
CogState Ltd is a leading provider of cognitive testing services for clinical trials, academic research, and healthcare. The company's business model revolves around using their digital tools and technologies to measure and enhance cognitive function in patients. By collaborating with pharmaceutical companies, academic institutions, and healthcare organizations, CogState Ltd aims to improve patient outcomes and accelerate the development of new treatments. With their expertise and extensive database, CogState Ltd offers customized solutions and prognostic insights to address the cognitive challenges faced in various industries.
CogState Ltd is primarily active in the healthcare and pharmaceutical industries.
The main competitors of CogState Ltd in the market are Cambridge Cognition Holdings PLC, Neurotrack Technologies Inc., and CogniFit Ltd. These companies also specialize in cognitive assessment and provide similar solutions and services. However, CogState Ltd distinguishes itself through its innovative technologies and partnerships, including collaborations with leading pharmaceutical companies. With its strong focus on enhancing the understanding and measurement of cognitive function, CogState Ltd continues to remain competitive in the market and deliver valuable solutions to its clients.
CogState Ltd is a renowned company with a rich history and background. Founded in 1999, CogState specializes in cognitive testing and offers innovative solutions to improve brain health assessment. With its headquarters in Melbourne, Australia, the company has expanded its global presence, serving various sectors including pharmaceuticals, biotechnology, and academic research. CogState has developed cutting-edge technologies and software platforms to deliver accurate and efficient cognitive assessments, benefiting patients, researchers, and professionals worldwide. Known for its advanced cognitive testing methods and commitment to enhancing brain health, CogState Ltd has established itself as a trusted industry leader.
CogState Ltd has achieved several significant milestones in its history. One key achievement is the development and commercialization of its pioneering cognitive testing technology, known as the CogState Computerized Cognitive Assessment Tool (CCAT). This innovative tool is widely utilized in clinical trials and research studies worldwide, enabling precise and objective measurement of cognitive function. Additionally, CogState Ltd has successfully established strategic partnerships with leading pharmaceutical companies, academic institutions, and healthcare providers, facilitating the widespread adoption of its solutions. The company continues to thrive through ongoing research and development, further cementing its position as a global leader in cognitive assessment technology.
CogState Ltd is primarily present in Australia, the United States, and Europe.
CogState Ltd represents a set of core values and a corporate philosophy that drive its operations. The company is committed to innovation, delivering cutting-edge solutions in the fields of cognitive assessment and clinical trials. CogState prioritizes integrity, ensuring transparent and ethical practices in all aspects of its business. With a focus on collaboration, CogState fosters strong partnerships to drive mutual success. The company values dedication to excellence, constantly striving for improvement and delivering high-quality products and services. CogState fosters a customer-centric approach, prioritizing customer satisfaction and delivering tailored solutions. Overall, CogState Ltd embodies a commitment to innovation, integrity, collaboration, excellence, and customer-centricity in its corporate philosophy.
Analitiki trenutno določajo povprečno ciljno ceno 2,13 USD za delnico CogState (mediana: 2,13 USD), kar pomeni −16,2 % glede na zadnjo ceno. Konsenz temelji na 6 ocenah.
7 analitikov trenutno ocenjuje delnico CogState: 6 priporoča nakup, 1 držanje in 0 prodajo. Za 2026 analitiki pričakujejo, da bo CogState ustvaril prihodke 128,65 Mio. USD in dobiček na delnico 0,09 USD.
Po trenutnem tečaju se delnica CogState trguje po 2,27 EUR (2,55 USD).
Delnica CogState (CGS.AX) je uvrščena na 2 borzah, med njimi: ASX (CGS.AX).
CogState Ltd is an innovative company specializing in the development and marketing of cognitive testing solutions. The company offers a wide range of products and services that can be used in the fields of pharmaceutical research, clinical diagnostics, and sports performance optimization. The three main business divisions of CogState Ltd include research and development of cognitive tests, clinical diagnostics and monitoring of patients with neurodegenerative disorders, and solutions for improving sports performance. The company's products are rooted in today's technology, as they are exclusively offered online. They allow for remote diagnosis and supervision of patients, saving time for therapists and improving diagnostic accuracy. The company's proprietary software platform enables researchers to effectively manage their studies and present study results in a concise format. CogState Ltd has a strategy in place to continue offering unique and expanding product offerings, allowing the company to remain a strong competitor in the industry.
pričakovane prihodki za CogState znašajo 128,65 Mio. USD. Ta vrednost temelji na trenutnih finančnih podatkih in odraža poslovno uspešnost podjetja.
pričakovane dobiček za CogState znaša 16,22 Mio. USD. Čisti dobiček odraža donosnost podjetja po odbitku vseh stroškov.
Razmerje cena-dobiček (P/E) CogState je trenutno 27,32. Razmerje P/E primerja trenutno ceno delnice z dobičkom na delnico in pomoči vlagateljem oceniti vrednost delnice CogState.
Razmerje cena-prihodki (P/S) CogState je trenutno 3,45. Razmerje P/S primerja tržno vrednost s celotnimi letnimi prihodki in služi kot kazalnik vrednotenja delnice CogState.
Eulerpool ocena kvalitete za CogState je 6/10.
ISIN CogState je AU000000CGS8. ISIN (International Securities Identification Number) je svetovni edinstven identifikator za vrednostne papirje.
Ticker CogState je CGS.AX. Ticker simbol se uporablja za trgovanje z delnicami CogState na borzi.
CogState delnica
CogState Konkurenčna skupina
CogState Ticker
CogState FIGI
Vse ključne kazalnike in poglobljeno analizo CogState v detaljnem pregledu
Naša analiza delnic CogState vključuje pomembne finančne kazalnike, kot so prihodki, dobiček, razmerje cena/dobiček (P/E), razmerje cena/prihodki (P/S), EBIT ter informacije o dividendah. Prav tako preučujemo aspekte, kot so delnice, tržna kapitalizacija, dolgovi, lastniški kapital in obveznosti CogState. Če iščete podrobnejše informacije o teh temah, na naših podstraneh nudimo obsežne analize: